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Noninvasive Evaluation of Liver Fibrosis 
and Portal Hypertension After Successful 
Portoenterostomy for Biliary Atresia
Maria Hukkinen,1 Jouko Lohi,2 Päivi Heikkilä,2 Reetta Kivisaari,3 Timo Jahnukainen,4 Hannu Jalanko,4 and Mikko P. Pakarinen1
We investigated noninvasive follow-up markers for histologic liver fibrosis and portal hypertension (PH) in patients 
with biliary atresia after successful portoenterostomy (PE). Among children with bilirubin <20 µmol/L after PE 
(n = 39), Metavir fibrosis stage was evaluated at PE and in follow-up protocol liver biopsies (n = 83). PH was de-
fined as endoscopically confirmed esophageal varices or thrombocytopenia associated with splenomegaly. The accu-
racy of liver biochemistry and stiffness in detecting liver fibrosis and PH was analyzed by the area under the 
receiving operating characteristic curve (AUROC) and multiple regression models. During a median native liver 
survival of 8.3 years (interquartile range 2.5-10.8 years), cirrhosis (Metavir F4) had developed in 51% of patients 
and PH in 54% of patients. Cirrhosis was equally common in all age tertiles of 1.2-2.1 years (n = 10/27), 3.9-5.8 
years (n = 12/28), and 9.0-14 years (n = 12/28). In the two oldest age tertiles, histologic liver fibrosis had progressed 
further in patients with PH than without PH (P < 0.001). PH was accurately predicted by the aspartate aminotrans-
ferase-to-platelet ratio index (APRI) (cutoff, 0.70; AUROC, 0.92), bile acids (cutoff, 49 µmol/L; AUROC, 0.91), 
and liver stiffness (cutoff, 16.9 kPa; AUROC, 0.89; P < 0.001 each) across all age tertiles. Liver stiffness was the 
most accurate predictor of cirrhosis overall (AUROC, 0.82; P < 0.001), whereas bilirubin was >11 µmol/L in the 
youngest tertile (AUROC, 0.91; P < 0.001), bile acids was >80 µmol/L in the middle tertile (AUROC, 0.81; P = 
0.009), and liver stiffness was >24 kPa in the oldest age tertile (AUROC, 0.96; P = 0.002). Conclusion: After suc-
cessful PE, development of PH associates with progression of liver fibrosis and can be accurately detected by APRI 
and stiffness. Liver stiffness most accurately identified cirrhosis in older children, whereas biochemical markers of 
cholestasis closely ref lected histologic cirrhosis in younger children. (H epatology Communications 2019;3:382-391).
Biliary atresia (BA) is a progressive fibroin-f lammatory cholangiopathy presenting exclu-sively in newborns and accounting for the 
majority of pediatric liver transplantations (LTs) 
worldwide.(1) Currently, clearance of jaundice (COJ) 
rates after portoenterostomy (PE) exceed 50%,(2-4) 
and up to 25% of patients survive with their native 
liver (NL) until adulthood.(3,5) Although patients 
who still have cholestasis after PE rapidly progress 
to end-stage liver disease and require LT for sur-
vival,(4,6) the disease course is far more variable after 
COJ. Following a successful PE, most patients sur-
vive with their NLs for many years.(2-5) However, 
during their disease course, the majority of children 
gradually progress to cirrhosis and develop symp-
toms of portal hypertension (PH), whereas others 
remain free from liver disease complications during 
childhood.(7-9)
Abbreviations: APRI, aspartate aminotransferase-to-platelet ratio index; AUROC, area under the receiver operating characteristic curve; BA, 
biliary atresia; BALF, BA liver fibrosis; CI, confidence interval; COJ, clearance of jaundice; GGT, gamma-glutamyltransferase; IQR, interquartile 
range; LT, liver transplantation; NL, native liver; PE, portoenterostomy; PH, portal hypertension; ROC, receiver operating characteristic; sens., 
sensitivity; spec., specificity.
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Accurate noninvasive tests for progressive liver 
fibrosis and the main complications of chronic liver 
disease would help to guide the post-PE follow-up 
of patients with normalized bilirubin levels and to 
serve as meaningful outcome measures for interven-
tional clinical trials. The limited number of previ-
ous studies analyzing such tests has also included 
children after failed PE without a systematic lon-
gitudinal assessment of postoperative liver histol-
ogy,(10-12) rendering the results unreliable. Liver 
stiffness is considered a useful predictor of fibrosis 
stage in children with various liver diseases(13-15) and 
has been reported to reflect the presence of esoph-
ageal and gastric varices after successful PE.(16) A 
previous study combining patients with both suc-
cessful and failed PE found an equation based on 
liver biochemistry accurate in predicting the degree 
of histologic fibrosis.(10) To systematically assess the 
accuracy of different noninvasive tests in reflecting 
fibrosis stage and the main complications of liver 
disease longitudinally after COJ, we related fol-
low-up liver biochemistry and liver stiffness with 
histologic liver fibrosis and PH in a national cohort 
of patients with BA who had cleared their jaundice 
after PE and underwent protocol liver biopsies and 
endoscopic variceal surveillance.
Patients and Methods
etHiCs
The study protocol was approved by the hospital 
ethical committee (protocol number 345/03/1372008). 
Institutional approval was renewed on July 21, 2017 
(§68 HUS/149/2017).
patients anD stuDy Design
Helsinki University Children’s Hospital is a nation-
wide referral center for pediatric hepatobiliary condi-
tions and has had a pediatric LT program since 1987. 
In the present study, we included all patients with BA 
managed in Helsinki between 1987 and 2016 and who 
had cleared their jaundice after PE (defined as normal-
ization of total bilirubin below 20 µmol/L postopera-
tively) and had undergone at least one follow-up liver 
biopsy. The diagnosis of BA was confirmed by intraop-
erative cholangiography when possible and histopathol-
ogy of the biliary remnant in all cases. At last follow-up, 
current medications and the total number of cholangitis 
episodes during follow-up were registered. Cholangitis 
was defined as febrile illness (>38°C) without any other 
identifiable cause treated with intravenous antibiotics.
liVeR Histology
All available follow-up liver biopsies (n = 83) and 
biopsies taken at PE (n = 34) of patients with BA 
who had cleared their jaundice were analyzed. Before 
centralization of BA management in 2005, follow-up 
biopsies were taken inconsistently. After 2005, pro-
tocol follow-up biopsies were scheduled 1, 5, and 
10 years after PE and at transition as well as when 
clinically indicated. The specimens were mainly core 
needle biopsies taken percutaneously under ultrasound 
guidance in general anesthesia for endoscopic variceal 
surveillance.(17) Blood count, liver biochemistry, and 
coagulation parameters were checked prior to biopsy, 
and patients were followed overnight in the hospi-
tal after the biopsy. Biopsies were graded for fibrosis 
using Herovici as well as hematoxylin and eosin stain-
ing and applying the Metavir staging where stage F1 
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corresponds to fibrous portal expansion without for-
mation of septa, stage F2 indicates portal fibrosis with 
occasional portal-to-portal septa, stage F3 indicates 
portal fibrosis with numerous septa, and stage F4 rep-
resents cirrhosis.(18) Biopsies containing at least 10 por-
tal areas were considered representative and included 
in the analyses. The specimens were re-reviewed by 
two experienced pediatric pathologists blinded to clin-
ical data until consensus was reached. The difference 
between Metavir stages at follow-up and at PE was 
defined as the change of Metavir stage after PE.
FolloW-up liVeR 
BioCHemistRy
Liver biochemistry, including blood platelet count, 
serum bile acids, and plasma concentrations of total 
and conjugated bilirubin, albumin, prealbumin, and 
gamma-glutamyltransferase (GGT), were registered 
at the time of follow-up liver biopsies. The aspar-
tate aminotransferase (AST)-to-platelet ratio index 
(APRI) was calculated according to the following 
 formula: ([AST/upper normal limit of normal] × 100) 
/ platelet count (109/L).(19) The biliary atresia liver 
fibrosis (BALF) score was calculated as 7.196 + (1.438 
× loge total bilirubin) + (0.434 × loge GGT) − (3.491 
× loge albumin) – (0.670 × loge age).(10)
liVeR stiFFness 
measuRement
Liver stiffness was measured by experienced pediat-
ric radiologists at the time of liver biopsy with a tran-
sient elastography device (FibroScan; Echosens, Paris, 
France).(20) The size of the probe was chosen accord-
ing to the manufacturer’s recommendations based on 
the patients’ thoracic perimeter. Results were based on 
a median of 10 validated measurements and reported 
in kilopascals. Only liver stiffness measurements 
with a success rate >60% and a ratio of interquartile 
range (IQR) and median <30% were included.(20) All 
measurements were preprandial and performed with 
patients awake and without sedation.
pH
Development of esophageal varices was monitored 
by performing annual upper gastrointestinal endosco-
pies, initiating at 12 months of age or at a younger age 
if bleeding were suspected.(4) Abdominal ultrasound 
was performed every 3 to 12 months at outpatient vis-
its. PH was defined as occurrence of varices at any time 
during follow-up or thrombocytopenia (<150 × 109/L) 
in association with splenomegaly in ultrasound (spleen 
length ≥2 z scores above the age- and sex-specific ref-
erence values).(8,21) The detection age of PH and its 
presence at the time of each liver biopsy was registered.
statistiCal metHoDs
Continuous variables were expressed as mean or 
median values with IQRs. Spearman rank correlation 
was used to examine associations between variables, 
and the Mann-Whitney U test was used to compare 
continuous variables. Follow-up liver biopsies and liver 
function test results were divided into tertiles according 
to age at examination. Receiver operating characteristic 
(ROC) curves and areas under the ROC (AUROCs) 
curves were used to evaluate the ability of liver bio-
chemistry and stiffness to detect histologic fibrosis as 
well as the presence of PH. In order to evaluate combi-
nations of different liver function tests and stiffness for 
detection of cirrhosis (Metavir stage F4) and PH, nat-
ural logarithms of liver function tests and stiffness were 
included as covariates in multiple logistic regression 
models. Only covariates showing correlations <0.70 
with each other were included in the same model. The 
predicted probabilities from logistic regression models 
were used to plot the respective ROC curves, and the 
multivariate models showing highest accuracy were 
used to create equations predicting the outcomes.(10) 
The optimal cut-off values were calculated using the 
maximum sum of specificityand sensitivity. The level of 
significance was set at P < 0.05, and all analyses were 
carried out with SPSS version 24.
Results
patient CHaRaCteRistiCs
A total of 40 children with BA who cleared their 
jaundice after PE were identified; these children com-
prised 63% of all patients with BA treated from 1987 to 
2016. One patient who underwent successful PE before 
2005 but no follow-up liver biopsy was excluded. Type 
3 BA was present in 90% of patients, and any associated 
malformations were detected in 39% of patients. After 
PE was performed (at a median age of 58 days), patients 
had cleared their jaundice by 2.5 months (IQR, 1.0-4.1 
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months) (Table 1). PH was first detected at a median 
age of 1.2 years (1.1-3.6 years) in 54% of patients, and 
18% received LT during follow-up (Table 1). Apart 
from 1 patient who underwent LT soon after detec-
tion of PH, esophageal varices were noticed during fol-
low-up in all others with PH. At the time of the study, 
no patient was listed for LT.
FolloW-up liVeR Biopsies anD 
pRogRession oF FiBRosis
We analyzed 83 follow-up liver biopsies (median 
of three biopsies/patient) (Table 1). Grouped 
according to age tertiles, the follow-up specimens 
were taken at a median age of 1.6 years (IQR, 1.2-
2.1 years; n = 27), 4.4 years (IQR, 3.9-5.8 years; n = 
28), or 10.8 years (IQR, 9.0-14.0 years; n = 28). At 
the time of biopsy, PH was present in 61% (n = 51) 
of patients, while grade 2 or greater esophageal vari-
ces were present in 57% (n = 47) of patients. Age at 
biopsy showed no correlation with Metavir fibrosis 
stage (r = −0.056; P = 0.613), and the proportions of 
liver biopsies showing high-grade fibrosis (Metavir 
stages F3 and F4) as well as cirrhosis (Metavir stage 
F4) were similar across the three age tertiles (63%, 
61%, and 54% for Metavir F3 and F4; 37%, 43%, 
and 43% for Metavir F4, respectively); the differ-
ence was not significant (NS). Patients who devel-
oped PH during follow-up showed higher Metavir 
fibrosis stage in their follow-up biopsies compared 
to PE (mean stage, 3.0 [IQR, 2.0-4.0] versus 2.4 
[IQR, 2.0-3.0]; P = 0.014), whereas no longitudi-
nal change in Metavir fibrosis stage was observed in 
patients remaining free from PH (mean stage, 2.4 
[IQR, 2.0-3.0] versus 2.5 [IQR, 2.0-3.0]), and the 
difference was NS (Fig. 1). In the two oldest age 
tertiles (median age of 4.4 and 10.8 years), Metavir 
fibrosis stage increased after PE significantly more 
among patients with PH than patients without PH 
(mean stage, 1.0 [IQR, 0.0-2.0] and mean stage, 
1.8 [IQR, 1.5-2.0] versus mean stage, 0.43 [IQR, 
0.0-2.0] and mean stage, −0.67 [IQR, −1.0-0.0]; 
P < 0.001 for both). The total number of cholangi-
tis episodes during follow-up showed no difference 
between patients with and without PH or between 
patients with and without cirrhosis in their last 
follow-up liver biopsy.
liVeR stiFFness anD liVeR 
BioCHemistRy in Relation to 
FiBRosis stage anD pH
Liver biochemistry was measured within a median 
of 1.0 day (IQR, 1.0-1.0 day) of liver biopsies. A 
total of 58 liver stiffness measurements among 34 
patients (87% of patients) were considered reliable 
and included for further analyses. They were per-
formed within a median of 1.0 day (IQR, 1.0-48 
days) of follow-up liver biopsies. Liver stiffness val-
ues and all biochemical values correlated with Metavir 
fibrosis stage (liver stiffness, r = 0.482, P < 0.001; bile 
acids, r = 0.479, P < 0.001; total bilirubin, r = 0.423, 
taBle 1. patient CHaRaCteRistiCs
All Patients (n = 39)
Age at last follow-up or at LT (years) 8.3 (2.5-10.8)
Age at PE (days) 58 (29-78)
Type of biliary atresia, n (%)
1 or 2 4 (10)
3 35 (90)
Associated malformations, n (%) 15 (39)
Polysplenia, n (%) 7 (5.9)
Time to COJ (months) 2.5 (1.0-4.1)
Metavir fibrosis stage at PE,* n (%)
1 2 (5.7)
2 18 (51)
3 11 (31)
4 3 (8.6)
Follow-up biopsies per patient, n 3 (2-4)
Metavir fibrosis stage in follow-up 
biopsies, n (%)
1 13 (16)
2 21 (25)
3 13 (16)
4 36 (43)
Ursodeoxycholic medication at last 
follow-up, n (%)
38 (97)
Prophylactic antibiotics at last 
follow-up, n (%)
35 (90)
Cholangitis episodes after PE, n (%) 2 (0-5)
Portal hypertension, n (%) 21 (54)
Age at portal hypertension detection 
(years)
1.3 (1.1-3.7)
Esophageal varices, n (%) 20 (51)
Age at detection of esophageal 
varices (years)
1.8 (1.2-5.2)
LT, n (%) 7 (18)
Age at LT (years) 7.4 (2.5-10.1)
Continuous data are reported as median with IQR.
*Liver histology at PE available for 34 patients.
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P < 0.001; APRI, r = 0.396, P < 0.001; GGT, r = 
0.358, P = 0.001; platelets, r = −0.301, P = 0.006; pre-
albumin, r = −0.287, P = 0.011). All biochemical val-
ues and liver stiffness values were significantly altered 
in the presence of cirrhosis or PH (Table 2).
pReDiCtion oF liVeR FiBRosis
None of the studied liver biochemistries, APRI, 
or liver stiffness were able to differentiate between 
Metavir fibrosis stages F1 through F3 (Fig. 2). In 
the whole cohort, liver stiffness was the most accu-
rate predictor of Metavir stage F4, with an AUROC 
value of 0.82 (Table 3; Fig. 3). Bilirubin, bile acids, 
and APRI performed best in the youngest age ter-
tile, whereas bile acids and liver stiffness performed 
best in the middle tertile (Table 3). Although liver 
stiffness was an inaccurate predictor of fibrosis in 
the youngest age tertile, it predicted cirrhosis with 
a moderate accuracy in the middle tertile and with 
a high accuracy in the oldest age tertile (Table 3; 
Fig. 3). In simple logistic regression, the highest 
coefficients for prediction of cirrhosis were obtained 
for the natural logarithms of bile acids, APRI, and 
liver stiffness (Supporting Table S1). The multiple 
regression models showing the highest accuracy for 
Fig. 1. Progression of liver fibrosis. Patients who (A) developed (n = 21) or (B) did not develop (n =18) portal hypertension during 
follow-up according to age tertiles are shown. *P < 0.05 compared to PE, **P < 0.05 compared to patients with portal hypertension for 
the change of Metavir fibrosis stage after PE. Data represent mean ± SEM.
taBle 2. liVeR BioCHemistRy anD stiFFness in Relation to HistologiC CiRRHosis 
(metaViR stage 4) anD poRtal HypeRtension at time oF FolloW-up liVeR Biopsy
Liver Function 
Test Measurements (n) Cirrhosis No Cirrhosis P Value Portal Hypertension
No Portal 
Hypertension P Value
Bilirubin 
(µmol/L)
83 17 (11-35) 7.0 (4.0-13) <0.001 14 (10-26) 5.0 (4.0-8.5) <0.001
GGT (U/L) 83 136 (58-308) 39 (25-92) 0.001 125 (41-307) 32 (19-57) <0.001
Bile acids 
(µmol/L)
75 126 (39-193) 28 (14-56) <0.001 126 (52-198) 20 (14-30) <0.001
Prealbumin 
(mg/L)
77 119 (98-163) 155 (133-171) 0.008 126 (96-155) 166 (146-180) <0.001
APRI 83 1.79 (1.15-2.68) 0.58 (0.35-1.52) <0.001 1.84 (1.30-2.41) 0.50 (0.26-2.41) <0.001
Platelets (× 
109/L)
83 117 (82-167) 192 (108-280) 0.001 101 (64-160) 252 (118-290) <0.001
Liver stiffness 
(kPa)
58 38.2 (23.9-60.9) 11.9 (6.3-23.7) <0.001 31 (17.9-60.1) 8.1 (5.6-13.4) <0.001
P values from Mann-Whitney U test are reported.
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prediction of cirrhosis included the natural loga-
rithms of bile acids, liver stiffness, prealbumin, and 
platelets as covariates, resulting in AUROC values 
of 0.98-0.88 with respective positive and negative 
predictive values of 0.90 and 0.84 for the whole 
cohort (Table 3). The accuracy of the published 
BALF score(10) remained below 0.75 for each age 
subgroup (Table 3).
pReDiCtion oF pH
APRI, bile acids, and liver stiffness were accurate 
predictors of PH, and they performed well across all 
age tertiles (Table 4; Fig. 3). GGT was accurate in 
younger age tertiles, whereas liver stiffness had the 
highest accuracy in older age tertiles (Table 4). In 
logistic regression, the highest coefficient for predic-
tion of PH was obtained for the natural logarithm of 
APRI (Supporting Table S2). The multiple regression 
model showing the highest accuracy for prediction of 
PH included the natural logarithms of APRI, liver 
stiffness, and age, and the equation derived from the 
model was a highly accurate predictor of PH for each 
age tertile (Table 4), with respective positive and neg-
ative predictive values of 0.97 and 0.95 for the whole 
cohort. For the prediction of grade 2 or greater esoph-
ageal varices, this score resulted in an AUROC value 
of 0.92 (95% confidence interval [CI], 0.84-1.00), with 
an optimal cut-off value of 0.63, sensitivity (sens.) of 
0.94, specificity (spec.) of 0.89, and respective positive 
and negative predictive values of 0.88 and 0.92.
Discussion
In this study, we longitudinally evaluated noninva-
sive markers of histologic liver fibrosis and PH among 
patients with BA who had cleared their jaundice after 
PE. Although APRI, bile acids, and liver stiffness 
were highly accurate in detecting the presence of PH 
Fig. 2. Liver biochemistry and stiffness in relation to Metavir fibrosis stage. *P < 0.05 compared to Metavir stage F4. The number of 
liver biopsies for each analysis is given on the x axis. The length of the box represents the interquartile range and the line through the 
middle of each box represents the median. Error bars show ± SEM.
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regardless of patient age, the accuracy of the fibrosis 
markers varied more across the age tertiles, and none 
were able to discriminate between Metavir stages F1 
through F3. Liver stiffness was the most accurate 
overall predictor of Metavir stage F4. Among children 
1 to 2 years of age, bilirubin, bile acids, and APRI 
detected cirrhosis with good accuracy, whereas among 
school-aged children, liver stiffness was highly accu-
rate for cirrhosis.
The progression of liver fibrosis and associated 
complications largely determine the prognosis of BA, 
which is profoundly distinct between patients who 
still have cholestasis compared to those whose bil-
irubin normalizes after PE.(6,10,22) After failed PE, 
patients nearly uniformly require LT by the age of 
2 years,(1) and consequently, the use of noninvasive 
methods to predict their inevitable and rapid pro-
gression toward end-stage liver disease may be less 
useful. On the other hand, after a successful PE and 
prolonged NL survival, some patients progress rapidly 
to cirrhosis, whereas in others, liver fibrosis may even 
resolve over time.(10) In our patient sample, Metavir 
fibrosis stage was unrelated to age and remained stable 
among patients free from PH, whereas it progressed 
during follow-up in others, demonstrating how devel-
opment of PH parallels the progression of histologic 
liver fibrosis after successful PE.
Reliable noninvasive markers of liver fibrosis 
would promote performance of interventional clinical 
trials designed to prolong NL survival in BA while 
sparing children from the burden and potential risks 
related to liver biopsies.(23,24) Although liver stiffness 
appears to be one of the most promising noninvasive 
methods reflecting fibrosis stage, it is influenced both 
by the etiology of liver disease and patient age.(25) 
Accordingly, the reported cutoffs and AUROC val-
ues for pediatric cirrhosis overlap markedly.(14,15,26) 
Previously determined cutoffs for cirrhosis at the time 
of PE are slightly lower compared to our results.(27,28) 
Because histologic inflammation and cholestasis are 
prominent at PE(4) and both may influence liver 
stiffness,(29-31) results obtained at the time of initial 
surgery are not directly comparable to the postoper-
ative period after COJ. Further, the published BALF 
score based on albumin, GGT, and bilirubin reflect-
ing follow-up fibrosis stage in an unselected sample 
of patients with BA showed no diagnostic accuracy 
in our cohort comprising solely patients with success-
ful PE.(10) These findings demonstrate that patients 
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Fig. 3. AUROCs for the best predictors of cirrhosis. (A) Cirrhosis (Metavir stage F4; n = 58 measurements). (B) Portal hypertension 
(n = 83 measurements).
taBle 4. FolloW-up liVeR BioCHemistRy anD liVeR stiFFness in tHe pReDiCtion oF poRtal 
HypeRtension
All Measurements Age 1.6 (1.2-2.1) Years
Age 4.4 (3.9-5.8) 
Years
Age 10.8 (9.0-14.0) 
Years
Liver Function 
Test n AUROC (95% CI)
Best Cutoff 
(sens., spec.) n AUROC (95% CI) n AUROC (95% CI) n AUROC (95% CI)
Total bilirubin 
(µmol/L)
83 0.83 (0.73-0.92)‡ 6.5 (0.90, 0.66) 27 0.86 (0.72-1.00)† 28 0.78 (0.61-0.96)* 28 0.82 (0.63-1.00)*
GGT (U/L) 83 0.79 (0.69-0.89)‡ 85.0 (0.63, 0.88) 27 0.92 (0.82-1.00)‡ 28 0.93 (0.84-1.00)‡ 28 0.78 (0.58-0.98)*
Bile acids 
(µmol/L)
75 0.91 (0.84-0.97)‡ 48.9 (0.77, 0.94) 25 0.95 (0.88-1.00)‡ 26 0.94 (0.84-1.00)‡ 24 0.90 (0.77-1.00)†
APRI 83 0.92 (0.85-1.00)‡ 0.70 (0.98, 0.88) 27 0.94 (0.85-1.00)‡ 28 0.94 (0.84-1.00)‡ 28 0.85 (0.58-1.00)†
Prealbumin 77 0.75 (0.64-0.86)‡ 152 (0.74, 0.70) 25 0.74 (0.53-0.95) 26 0.80 (0.62-0.97)* 26 0.86 (0.71-1.00)†
Platelets (× 
109/L)
83 0.91 (0.85-0.97)‡ 164 (0.89, 0.78) 27 0.82 (0.67-0.98)† 28 0.85 (0.71-1.00)† 28 0.99 (0.95-1.00)‡
Liver stiffness 
(kPa)
58 0.89 (0.81-0.97)‡ 16.9 (0.77, 0.87) 20 0.84 (0.67-1.00)* 21 0.94 (0.84-1.00)‡ 17 0.96 (0.87-1.00)†
Age (years) 83 0.71 (0.59-0.82)† 2.16 (0.88, 0.50) 27 0.68 (0.46-0.90) 28 0.57 (0.35-0.80) 28 0.52 (0.25-0.79)
Combination of 
APRI, liver 
stiffness, and 
age§
58 0.98 (0.94-1.00)‡ 0.44 (0.97, 0.96) 20 0.99 (0.96-1.00)‡ 21 0.95 (0.85-1.00)‡ 17 1.00 (1.00−1.00)†
AUROC values with 95% CIs are reported for all available measurements as well as for subgroups based on age tertiles at time of liver 
biochemistry measurement. Age at biopsy reported as median with IQR.
*P < 0.05, †P < 0.01, ‡P ≤ 0.001. §Based on the equation –5.282 + (3.075 × loge APRI) + (1.715 × loge Liver stiffness) + (0.251 × loge Age).
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achieving COJ are not directly comparable to infants 
with BA who are waiting for PE nor to older patients 
who have failed to normalize their bilirubin after PE.
Although liver stiffness was a moderately accurate 
predictor of cirrhosis in the entire patient cohort, 
none of the tests studied were able to differentiate 
between Metavir stages F1 through F3. This find-
ing is in line with previous studies comparing liver 
stiffness and APRI to Metavir fibrosis stage obtained 
at PE.(27,28,32,33) As in this study, combination scores 
based on different variables may result in higher 
accuracy and better discrimination than individual 
liver function tests but are less feasible for clinical 
use. In our study, the accuracy of cirrhosis predic-
tors showed variability across the age tertiles. In the 
youngest age tertile at a median age of 1.6 years, cir-
rhosis was accurately predicted by bilirubin values >11 
µmol/L and bile acid values >80 µmol/L, suggesting 
cirrhosis develops early without efficient re-estab-
lishment of bile flow by PE. The predictive value 
of liver biochemistry decreased with increasing age; 
indeed, long-term survivors with NL and compen-
sated cirrhosis may present with almost normal liver 
biochemistry.(5) In older children, however, liver stiff-
ness predicted cirrhosis with high accuracy. Despite 
including only successfully completed high-quality 
measurements, we did not find liver stiffness as a 
statistically significant predictor of cirrhosis in the 
youngest age group. This may relate to the dynamic 
nature of liver damage and remodeling among infants 
soon after PE or inherently poor reproducibility of 
liver stiffness measurement in small babies. As many 
as two-thirds of liver stiffness measurements per-
formed among children aged <2 years have been 
reported to be unreliable.(25)
In clinical practice, recognizing significant PH 
is of particular importance as it influences patient 
well-being and may warrant endoscopic interven-
tions for esophageal varices.(8) Primary prophylaxis 
of high-risk varices among children has been recom-
mended due to the mortality and morbidity related 
to acute gastrointestinal bleeding episodes.(34) In our 
series, apart from 1 patient with PH who underwent 
LT at a young age, esophageal varices were observed 
in others soon after detection of PH. According to 
our findings, liver stiffness >16.9 kPa, APRI >0.70, 
and bile acids >50 µmol/L discriminated patients 
with PH with high accuracy. Similar liver stiffness 
cutoffs have been shown to predict clinically signifi-
cant varices among patients with BA with normalized 
bilirubin.(16) In addition, similar liver stiffness and 
APRI values correlate with PH defined by hepatic 
venous pressure gradient measurement, supporting 
the application of these cut-off values into clinical 
practice.(35-37) Overall, APRI was the best predictor 
of PH. A cutoff of 0.60 would have correctly clas-
sified 98% of cases that resulted in six false-positive 
results, and such a cutoff could be used in clinical 
practice to select which patients should undergo 
endoscopic screening for varices.
This study had some limitations, including its ret-
rospective design and some missing liver function 
test results, although investigations were performed 
prospectively according to our institutional follow-up 
protocol. Synchronous reliable liver stiffness mea-
surements were available for only 70% of biopsies. 
However, because the available measurements fulfilled 
the recommended methodologic criteria(20) and the 
patient age distribution was relatively uniform, we con-
sider the results reliable and valuable. Other strengths 
of this study include the protocol-based longitudinal 
collection of liver biopsies and performance of surveil-
lance endoscopies for reliable detection of PH.
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